株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

顕微鏡的多発性血管炎(MPA):パイプライン分析

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 302487
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.79円で換算しております。
Back to Top
顕微鏡的多発性血管炎(MPA):パイプライン分析 Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 50 Pages
概要

顕微鏡的多発性血管炎(MPA)は、現在はまだ未知の病であり、血管の炎症の結果として発症し、臓器系に損傷を及ぼします。MPAによる損傷を最も受けやすい部位として、腎臓や肺、神経、皮膚、関節などがあります。主な症状には、息切れや咳、発熱、食欲不振、発疹、筋肉痛・関節痛などが挙げられます。また、主な治療法には免疫抑制療法などがあります。

当レポートでは、世界各国での顕微鏡的多発性血管炎(MPA)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

顕微鏡的多発性血管炎の概要

治療薬の開発

  • 顕微鏡的多発性血管炎向けパイプライン製品:概要
  • 顕微鏡的多発性血管炎向けパイプライン製品:比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Aprogen, Inc.
  • ChemoCentryx, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • Teijin Pharma Limited

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • belimumab
  • CCX-168
  • immune globulin (human)
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar

最新パイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8942IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 2, 3 and 2 respectively.

Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Microscopic Polyangiitis (MPA) - Overview
  • Microscopic Polyangiitis (MPA) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
    • Celltrion Inc
    • ChemoCentryx Inc
    • Coherus BioSciences Inc
    • GlaxoSmithKline Plc
    • Panacea Biotec Ltd
    • Sandoz International GmbH
    • Teijin Pharma Ltd
  • Microscopic Polyangiitis (MPA) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Microscopic Polyangiitis (MPA) - Drug Profiles
    • avacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Microscopic Polyangiitis (MPA) - Dormant Projects
  • Microscopic Polyangiitis (MPA) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
      • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Celltrion Inc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences Inc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Ltd, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top